The Brazilian Peritoneal Dialysis Multicenter Study (BRAZPD) : characterization of the cohort.

The Brazilian Peritoneal Dialysis Multicenter Study (BRAZPD) was launched in December 2004 aiming to collect data monthly and continuously from a representative cohort, allowing for a continuous snapshot of the peritoneal dialysis (PD) reality in the country. This is an observational study of PD patients comprising follow-up from December 2004 to February 2007 (mean follow-up of 13.6 months-ranging from 1 to 26 months) in 114 Brazilian centers. All centers report data through a central web-based database. After an initial baseline retrospective data collection, all patients are followed prospectively every month until they drop out from the PD program. Total number of patients recruited until February 2007 was 3226 (2094 incident patients). Mean age was 54+/-19 years (37% above 65 years old), with 55% females and 64% Caucasians. The more frequent causes of renal failure were diabetic nephropathy (34%), renal vascular disease associated with hypertension (26%), and glomerulopathies (13%). The most common comorbidities were hypertension (76%), diabetes (36%), and ischemic heart disease (23%). Automated PD (APD) was the modality utilized in 53%. The estimated overall peritonitis rate was 1 episode per 30 patient-months (most frequently due to Staphylococcus aureus). The total dropout rate was 33%, mainly due to deaths, whereas 20% of dropouts were due to renal transplant. The gross mortality was 17.6% and the main causes of mortality were cardiovascular diseases (40%) and infections (15%). The initial results of this first Brazilian PD registry provide a unique opportunity to develop future clinical studies addressing specific PD questions in the Brazilian reality and context.

Corporeal weight gain and metabolic syndrome in living kidney donors after nephrectomy.

UNLABELLED: The number of healthy individuals undergoing unilateral nephrectomy for kidney donation is increasing world-wide. Obesity and nephron reduction could promote a decline in the glomerular filtration rate (GFR) and an increase in urinary protein excretion in these individuals. Metabolic Syndrome (MS) is also a risk factor for these patients. This study evaluated GFR, urinary protein excretion, and the possibility of one or more components of MS in this group. METHODS: Twenty live kidney donors were evaluated at an average of 10 years after nephrectomy. We obtained measurements of systolic blood pressure, diastolic blood pressure, and waist circumference. We estimated renal function, urinary protein excretion, triglycerides, high-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and fasting plasma glucose levels. The GFR was calculated through the estimated creatinine clearance using the Cokcroft-Gault equation (eGFR). RESULTS: Of the 20 participants, four developed MS. The patients with a greater number of MS components showed a greater eGFR. Only seven donors (35%) showed a normal blood pressure. Serum creatinine level changes were observed in three patients, and in five there was increased urinary protein excretion. CONCLUSION: This study showed the possibility that corporeal weight gain and MS may be additional overburdens on the GFR of the remaining kidney.

Determination of systemic haemodynamic alterations induced by slow-release nifedipine in elderly hypertensive patients using a non-invasive method: double-blind cross-sectional random study.

We evaluated the systemic haemodynamic alterations induced by slow-release nifedipine administered to elderly hypertensive patients, 20 mg twice daily by the oral route for 4 weeks. A non-invasive chest electrical bio-impedance method was used to detect changes in stroke volume and cardiac output. The random, double-blind, crossover study showed variations in measurements made in the supine and in the standing position: delta -18.0% (P < 0.001) and delta -14.9% (P < 0.001) for mean arterial pressure; delta -16.5% (P < 0.01) and delta -34.9% (P < 0.01) for total peripheral resistance; and delta +8.1% (P < 0.05) and delta +12.6% (P < 0.01) for heart rate, respectively. In contrast, cardiac output and stroke volume were the same when measured in the supine and standing positions both when compared with the placebo period and when compared with each other. We conclude that slow-release nifedipine is effective in reducing systemic blood pressure levels of elderly subjects and that this phenomenon occurs without reductions in cardiac output.

[Captopril in the treatment of patients with congestive heart failure. Its bicycle ergometry evaluation]. / Captopril no tratamento de pacientes com insuficiência cardíaca congestiva. Avaliação cicloergométrica.

PURPOSE: To analyze the physical performance of the patients with congestive heart failure (CHF), grades I and II of the New York Heart Association (NYHA), submitted to ergometric test: 1) under conventional treatment with digitalis and diuretic; 2) with an angiotensin converting enzyme inhibitor, captopril, associate with conventional treatment; 3) using captopril associated with digitalis or diuretic. METHODS: A randomized double blind study was performed in 20 patients with CHF (I and II-NYHA) submitted to ergometric test in different therapeutic phases. The initial workload was 5 watts and load was increased until the appearance of limiting symptoms. RESULTS: The introduction of captopril to the conventional treatment for CHF or associated with digitalis or diuretic promotes significant increase in the duration of the physical exercise, in the oxygen consumption and in the total workload during the ergometric test. CONCLUSION: In the initial forms of CHF, captopril provides better physical performance when compared with conventional treatment and the diuretic treatment can be changed for the angiotensin converting enzyme inhibitor with equal efficacy.

[Captopril in mild and moderate arterial hypertension resistant to diuretic therapy. A multicenter study]. / Captopril na hipertensão arterial level e moderada resistente à diureticoterapia. Estudo multicêntrico.

PURPOSE: To evaluate the antihypertensive effect of captopril in mild and moderate hypertensive patients uncontrolled with diuretics. METHODS: Low dose of captopril (25 to 50 mg) bid were associated during 9 weeks in 120 patients previously treated with 100 mg of hydrochlorothiazide. A subgroup of patients (74) were followed additionally for 3 weeks with the same dose of the drugs administered as a single dose. The patients were clinically evaluated after two weeks placebo, and each three weeks of active drugs. Blood pressure normalization were considered when diastolic arterial pressure was < or = 90 mmHg. Laboratory tests were measured before diuretic, before captopril and at the end of combined twelve weeks treatment. RESULTS: After 15 days washout, the baseline supine arterial pressure, 168 +/- 2/ 109 +/- 1 mmHg decrease significantly with diuretic to 151 +/- 1/ 101 +/- 1 mmHg and the drop was further increased with captopril b.i.d., with a mean dose of 44 +/- 1 mg, to 137 +/- 1/ 90 +/- 1 mmHg. Blood pressure normalization was obtained in 58% patients with captopril b.i.d. and in 63% as single dose. Blood pressure normalization was achieved in 63% of non-white patients and in 56% patients over 45 years old. Plasmatic potassium decreased significantly with diuretic and did not recovered when captopril was associated. CONCLUSION: Our results indicate that the addition of low dose of captopril twice or once a day may result in a marked additional blood pressure reduction in cases of insufficient control by the diuretic alone.

Comparison of the hemodynamic effects of sodium acetate in euvolemic dogs and in dogs submitted to hemorrhagic shock.

We determined the dose-response relationship of systemic hemodynamics with graded intravenous infusions of sodium acetate (0.75, 1.50 and 3.00 microEq kg-1 min-1) in a group of dogs in the euvolemic state (N = 10) and in animals submitted to severe hemorrhagic shock (N = 7). Sodium acetate had a marked vasodilator effect on both groups, decreasing total peripheral resistance by 36.6% and 55.1%, respectively. Cardiac index increased simultaneously by 68.4% and 143.0%, respectively. Sodium acetate induced an approximate normalization of cardiac index and peripheral resistance at the highest infusion rate in the animals submitted to hemorrhagic shock. The normalization of cardiac output was due to a marked increase in heart rate in euvolemic dogs and to an increase in stroke volume in shocked animals. The hyperkinetic state of the circulation induced by the drug and a possible inotropic action of sodium acetate either direct or indirect could explain the different patterns of response.

Hemodynamic mechanism of blood pressure response to captopril in human malignant hypertension.

The hemodynamic mechanism of blood pressure response to angiotensin blockade is well established in "benign" but not in human malignant hypertension. We studied the changes in mean arterial pressure (MAP), cardiac index (CI), pulmonary wedge pressure (PWP), and in plasma volume (PV) induced by a single oral dose of captopril (150 mg) in 11 patients with malignant hypertension. Two hours after captopril, MAP fell from 178.5 +/- 5.8 to 151.8 +/- 7.8 mm Hg (p less than 0.001) (means +/- SEM) due to a fall in total peripheral resistance (TPR) (from 54.8 +/- 6.8 to 46.4 +/- 1.6 arbitrary units, p less than 0.001). However, there was a simultaneous increase in CI (from 3.29 +/- 0.13 to 3.70 +/- 0.15 liter/min/m2, p less than 0.001), and a decrease in PWP (from 15.3 +/- 3.5 to 11.0 +/- 2.5 mm Hg, p less than 0.001), while PV remained unchanged (from 4.02 +/- 0.26 to 4.12 +/- 0.12 liters, n.s.). Our data show that, in human malignant hypertension, blood pressure response to captopril is due to a decrease in TPR, but in contrast to benign hypertension, there is also a simultaneous increase in CI. Our results suggest that, in malignant hypertension, potentially high CI levels are artificially normalized by the increased TPR and may be fully disclosed by vasodilation.